SuperGen Announces Identification of new Class of Etk/Bmx Kinase Inhibitors at the AACR 100th Annual Meeting 2009
News Apr 23, 2009
SuperGen Inc. has announced as part of a series of presentations at the 100th Annual Meeting of the American Association for Cancer Research (AACR), that it has identified a new class of small molecules which successfully inhibit Etk/Bmx kinase in preclinical cancer models.
Entitled, “Targeting Etk/Bmx kinase with small molecule inhibitors,” the poster highlights data indicating that SuperGen lead compounds in this class inhibit the autophosphorylation of Etk, the activation of STAT3 downstream of EGF stimulation, and inhibit the colony formation of prostate and liver cancer cells lines in soft agar.
“SuperGen is committed to bringing first in class drugs into the clinic against cancer drug targets, and Etk/Bmx represents another one of these targets,” said Dr. David Bearss, SuperGen’s Chief Scientific Officer. “We are excited about selecting a clinical candidate for this program and think this program signifies another example of what our company and drug discovery technology can accomplish.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019